Recorded Chinese product: 尼可刹米注射液尼可刹米注射液
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 江苏吴中医药集团有限公司苏州制药厂Chinese legal name: 江苏吴中医药集团有限公司苏州制药厂
主要成分Active Ingredients
- 尼可刹米Nike Shami
药物知识说明
尼可刹米是一种在国家药监局注册认定的药品。该药品含有尼可刹米-acb919fb等成分。
该药品关联的活性成分包括：尼可刹米Nike Shami。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：江苏吴中医药集团有限公司苏州制药厂Chinese legal name: 江苏吴中医药集团有限公司苏州制药厂。
您可以探索含有相同成分的其他药品：尼可刹米-acb919fb成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 尼可刹米注射液) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 尼可刹米Nike Shami.
Manufacturers recorded for this product: 江苏吴中医药集团有限公司苏州制药厂Chinese legal name: 江苏吴中医药集团有限公司苏州制药厂.
Explore other medicines containing the same ingredient: 尼可刹米 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 尼可刹米注射液Recorded Chinese product: 尼可刹米注射液
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 1.5ml:0.375g1.5 mL:0.375 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 江苏吴中医药集团有限公司苏州制药厂Chinese legal name: 江苏吴中医药集团有限公司苏州制药厂
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H32022772
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H32022772
Manufacturer
Chinese legal name: 江苏吴中医药集团有限公司苏州制药厂 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H32022772
生产企业
江苏吴中医药集团有限公司苏州制药厂(国产)
适应症
用于中枢性呼吸抑制及各种原因引起的呼吸抑制。
用法用量
常用量：皮下注射、肌肉或静脉注射，每次0.25～0.5g。极量：皮下、肌内或静脉注射，一次1.25g。
不良反应
常见面部刺激症、烦躁不安、抽搐、恶心呕吐等。大剂量时可出现血压升高、心悸、出汗、面部潮红、呕吐、震颤、心律失常、惊厥、甚至昏迷。
禁忌
抽搐及惊厥患者。
注意事项
作用时间短暂，应视病情间隔给药。
贮藏
遮光，密闭保存。
规格
1.5ml:0.375g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.